Shield Therapeutics plc (LON:STX – Get Free Report) was down 3.4% during trading on Wednesday . The stock traded as low as GBX 2.80 ($0.04) and last traded at GBX 2.80 ($0.04). Approximately 2,343,094 shares changed hands during trading, a decline of 48% from the average daily volume of 4,502,179 shares. The stock had previously closed at GBX 2.90 ($0.04).
Shield Therapeutics Price Performance
The business’s fifty day moving average price is GBX 3.76 and its 200 day moving average price is GBX 2.99. The company has a debt-to-equity ratio of 3,691.50, a current ratio of 1.05 and a quick ratio of 2.16. The stock has a market cap of £22.52 million, a P/E ratio of -72.50 and a beta of 1.42.
About Shield Therapeutics
Shield Therapeutics plc, a specialty pharmaceutical company, focuses on commercialization of pharmaceuticals to treat unmet medical needs. Its lead product is Accrufer/Feraccru, a non-salt based oral therapy for adults to treat the iron deficiency with or without anemia. Shield Therapeutics plc was founded in 2008 and is based in Gateshead, the United Kingdom.
Read More
- Five stocks we like better than Shield Therapeutics
- The How and Why of Investing in Gold Stocks
- Why Palo Alto Networks’ Multi-Year Uptrend Is Far From Over
- How Can Retail Investors Trade the Toronto Stock Exchange (TSX)?
- 3 Rock-Solid Buying Opportunities in the Market Right Now
- What is the Australian Securities Exchange (ASX)
- TJX Companies Stock Poised to Hit a New High This Year
Receive News & Ratings for Shield Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shield Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
